ICU Medical Inc — MarketDX

ICUI▲

ICU Medical Q2 Earnings Beat Estimates on Infusion Systems Strength

ICU Medical reported second quarter results that beat analyst expectations, driven by strong performance in its Infusion Systems and Consumables segments. Revenue came in at $547.9 million versus estimates of $532.8 million, while adjusted EPS of $2.37 beat the $1.91 consensus by 23.8%. The company also raised its full-year adjusted EPS guidance to $8.80 at the midpoint, above analyst estimates by 7.8%. During the earnings call, analysts questioned management about the durability of growth, with CEO Vivek Jain attributing Infusion Systems strength to competitive wins and earlier installations rather than a broader replacement cycle, and noting that organic growth should continue at or above a 6% rate.

ICUI ▲

StockStory·11dRead more ▾

ICUI▲2

ICU Medical beats Q2 estimates and raises full-year EPS guidance

ICU Medical reported second-quarter results that surpassed Wall Street expectations and issued full-year adjusted EPS guidance above analyst estimates. Revenue rose 1.5% year-on-year to $551.7 million, beating the consensus of $532.8 million. Adjusted EPS came in at $2.37, 23.8% above the $1.91 estimate, while adjusted EBITDA of $110 million exceeded the $101.1 million forecast. The company guided for full-year adjusted EPS of $8.80 at the midpoint, topping analyst projections by 7.8%, and full-year EBITDA of $425 million, above the $417 million consensus.

ICUI ▲

Yahoo Finance·20dRead more ▾

ICUI

Biotech Stocks ANIK, CHE, ICUI, NBIX, RPRX Hit 52-Week Highs on Earnings and Pipeline News

Several biotech stocks reached 52-week highs on July 29, 2026, driven by second-quarter financial results and clinical updates. Anika Therapeutics rose over 6% to $17.75 after reporting second-quarter revenue of $32.6 million, a 17% year-over-year increase, and net income of $3.3 million, while revising its 2026 total revenue growth guidance to 5% to 10%. Chemed Corporation climbed over 4% to $551.68 as its second-quarter revenue grew 8.8% to $673 million, with its VITAS Healthcare unit contributing $443.4 million in patient revenue and a 9% increase in admissions, and the company raised its full-year revenue growth estimate to 8.25% to 9.25%. ICU Medical hit an intraday high of $170.48 ahead of its August 6 earnings report, following a first quarter in which infusion systems product revenue grew 9% to $179 million despite a 12% overall GAAP revenue decline to $530 million due to a divestiture. Neurocrine Biosciences reached $183.50 ahead of its July 30 earnings release, after first-quarter net product sales surged 44% to $811 million and the company acquired Soleno Therapeutics in May 2026. Royalty Pharma touched $60.44, reporting a 13% increase in first-quarter royalty receipts to $887 million and projecting full-year royalty receipts between $3.32 billion and $3.45 billion, with second-quarter results due on August 5.

ANIK ▲CHE ▲NBIX ▲RPRX ▲ICUI

RTTNews·27dRead more ▾

ICUI▲

IV Equipment Market Forecast to Reach USD 23.92 Billion by 2031

The global IV equipment market is projected to grow from USD 17.82 billion in 2026 to USD 23.92 billion by 2031, at a compound annual growth rate of 6.1%. Growth is driven by the rising prevalence of chronic diseases, increasing demand for hospital services, and a shift toward home-based and outpatient care. The needle-free connectors and extension sets segment is expected to see remarkable growth due to enhanced safety features and reduced needlestick injuries, while medication administration remains the dominant application. North America leads the regional market, supported by a strong healthcare infrastructure and high adoption of advanced technologies. Key players include Becton, Dickinson and Company, B. Braun SE, Fresenius SE & Co. KGaA, ICU Medical, Inc., and Terumo Corporation.

4543.JP ▲BDX ▲FRE.XETRA ▲ICUI ▲

GlobeNewswire·57dRead more ▾

Biotech & Genomic Medicine▼

StockStory names BioMarin and Boston Scientific as top healthcare picks, flags ICU Medical as a sell

StockStory has identified BioMarin Pharmaceutical and Boston Scientific as two healthcare stocks poised for long-term outperformance, while recommending investors avoid ICU Medical. BioMarin, which develops therapies for rare genetic disorders, posted 14.5% annual sales growth over the past two years and is projected to accelerate to 28.4% revenue growth in the next twelve months, with its free cash flow margin expanding by 5.6 percentage points over five years. Boston Scientific, a maker of minimally invasive medical devices, achieved 15.7% organic revenue growth and grew earnings per share at a 24.2% annual rate over five years, supported by a 9.1 percentage point increase in free cash flow margin. In contrast, ICU Medical saw sales decline 1.6% annually over two years, earnings per share growth of just 2.9% annually over five years trailing revenue gains, and a return on invested capital of only 0.9%, signaling weak profitability and investment challenges.

BMRN ▲BSX ▲ICUI ▼

Biotech & Genomic Medicine ▲

StockStory·61dRead more ▾

ICUI

Merit Medical Systems Q1 revenue beats estimates, raises full-year guidance

Merit Medical Systems reported first-quarter revenues of $381.9 million, up 7.5% year on year and exceeding analyst expectations by 1.2%. The company also beat earnings per share estimates and raised its full-year guidance, the highest raise among the four medical devices and supplies stocks tracked in the cardiology, neurology, and vascular segment. ICU Medical posted revenues of $525.8 million, down 12.3% year on year but still beating estimates by 1.2%, while Artivion's revenues grew 17.5% to $116.3 million but missed earnings estimates and provided weak guidance, sending its stock down 38.1%. Penumbra's revenues rose 15.6% to $374.8 million, topping estimates by 0.7%, though it missed earnings per share forecasts. Overall, the group's revenues beat consensus estimates by 0.9% on average, but share prices have fallen 6.2% since reporting.

MMSI ▲AORT ▼ICUI PEN

Yahoo Finance·62dRead more ▾

ICUI▼

ICU Medical Stock Analysis: Hold or Sell After Q1 Earnings

ICU Medical's stock has underperformed the market, losing 3.3% over the past six months while the S&P 500 gained 6.3%. The company's revenue has declined at an annualized rate of 1.6% over the last two years, a sharp reversal from its five-year trend. Earnings per share grew at a compounded annual rate of just 2.9% over five years, well below its 11.8% annualized revenue growth, indicating declining profitability. Its five-year average return on invested capital was 0.9%, below the typical cost of capital for healthcare companies. The stock trades at 16.3 times forward earnings, and analysts see limited upside relative to potential downside, suggesting better opportunities exist elsewhere.

ICUI ▼

Yahoo Finance·62dRead more ▾

ICUI▲

ICU Medical Outshines Medline as a Value Stock

ICU Medical is seen as a better value stock than Medline based on Zacks Investment Research analysis. ICU Medical holds a Zacks Rank of #2 (Buy) and a Value grade of B, while Medline has a Zacks Rank of #3 (Hold) and a Value grade of C. ICU Medical's forward P/E ratio stands at 16.90 compared to Medline's 24.08, and its PEG ratio is 1.54 versus Medline's 5.19. Additionally, ICU Medical's price-to-book ratio is 1.63, lower than Medline's 2.47. The improving earnings outlook and stronger valuation metrics make ICU Medical the preferred choice for value investors.

ICUI ▲MDLN ▼

Zacks Investment Research·69dRead more ▾